Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib

被引：0
作者：
Xu, X. [1 ,2 ,3 ]
Li, N. [1 ]
Fan, Y. [1 ,2 ]
机构：
[1] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Chinese Acad Sci, Hangzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
ALK; non-small cell lung cancer (NSCLC); leptomeningeal metastases (LM);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-09
引用
收藏
页码：S445 / S445
页数：1
相关论文
共 50 条
[31]   Alectinib efficacy in advanced lung adenocarcinoma with coexistence of a novel ALK-MTUS2 and STRN3-ALK double fusion: A case report and literature review [J].
Qiu, Xirui ;
Wei, Yu ;
Wang, Xiaoxiao ;
Xu, Siyan ;
Zhang, Yaru ;
He, Hailang ;
Zhou, Xianmei .
ONCOLOGY LETTERS, 2025, 30 (03)
[32]   Epidemiology of EML4-ALK translocations in a small, German non-small-cell lung cancer patient cohort [J].
Schildgen, Verena ;
Lochl, Vincenza ;
Luesebrink, Jessica ;
Brockmann, Michael ;
Schildgen, Oliver .
PERSONALIZED MEDICINE, 2012, 9 (08) :801-803
[33]   A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib [J].
Chen, Hua-fei ;
Wang, Wen-xian ;
Xu, Chun-wei ;
Huang, Li-chao ;
Li, Xiao-feng ;
Lan, Gang ;
Zhai, Zhan-qiang ;
Zhu, You-cai ;
Du, Kai-qi ;
Lei, Lei ;
Fang, Mei-yu .
LUNG CANCER, 2020, 142 :59-62
[34]   Evaluation of EML4-ALK Fusion Proteins in Non-Small Cell Lung Cancer Using Small Molecule Inhibitors [J].
Li, Yongjun ;
Ye, Xiaofen ;
Liu, Jinfeng ;
Zha, Jiping ;
Pei, Lin .
NEOPLASIA, 2011, 13 (01) :1-U14
[35]   Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review [J].
Li, Pei ;
Ju, Xiao ;
Yang, Guangjian .
DISCOVER ONCOLOGY, 2024, 15 (01)
[36]   A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer [J].
Xu, Xinyan ;
Liu, Di ;
Wen, Junmiao ;
Chen, Jiayan ;
Fan, Min .
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) :2500-2507
[37]   The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer [J].
Lin, Yen-Ting ;
Liu, Yi-Nan ;
Shih, Jin-Yuan .
FRONTIERS IN ONCOLOGY, 2019, 9
[38]   Confirmation of lung adenocarcinoma as the primary cancer with detection of EML4-ALK rearrangement using next-generation sequencing: a case study [J].
Mo, Yijun ;
Lin, Lina ;
Zhang, Jianhua ;
Zhong, Yan ;
Zhang, Tao ;
Zhong, Chenghua ;
Yan, Jun ;
Kuang, Jun ;
Guo, Quanwei ;
Tan, Jianfeng ;
Li, Dongfang ;
Wu, Mengxi .
PATHOLOGY RESEARCH AND PRACTICE, 2022, 238
[39]   Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report [J].
Zhou, Huamiao ;
Xu, Binyue ;
Xu, Jili ;
Zhu, Guomeng ;
Guo, Yong .
FRONTIERS IN ONCOLOGY, 2021, 11
[40]   Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report [J].
Gu, Xiaodong ;
Wang, Wenxian ;
Wu, Wei ;
Zhang, Yiping ;
Shao, Lan ;
Santarpia, Mariacarmela ;
Christopoulos, Petros ;
Myall, Nathaniel J. ;
Shi, Zhiyong ;
Lou, Guangyuan .
TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (05) :902-909
12345